NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Dr. Stupp. Wrong again.

Here is what he said.

The presumed benefit of DCVax seems to be restricted to patients with MGMT-methylated tumors (Supplement 2, eFigure 1). The authors do not provide an explanation for this observation nor for the counterintuitive benefit seen in the elderly (age ≥65 years) and in those with only partially resected tumors.

Dr. Rago, and Dr. Stupp knows this too, understand there is far more mutation targets in methylated mgmt-tumors. Dr. Stupp ignores this as he is a proponent of only Optune and Temodar. Just like Dr. Stupp ignores that reducing Temodar dose might maintain interference with tumor repair but not, as it has been doing to patients all these years, reducing the ability of t-cells to do their job.

Dr. Stupp also knows, but forgets, that patients 65 and older are, on average, highly methylated mgmt and mesenchymal, again providing a high level of mutations for DCVax-l instructed t-cells to attack.

Dr. Stupp also knows, but conveniently forgets, that patients with partially resected tumors actually need further tumor clearance than the surgeon can provide. Thus a patient who would otherwise die early because of poor surgical tumor clearance, instead has his residual tumor attacked by infiltrating t-cells previously instructed by DCVax-l. This also provides antigen targeting for further immune monitoring.

Dr. Stupp also ignore very long term survival proof in DCVax-l patients, because he knows Optune can’t do this nearly as well due to tumor escape from the tumor treating field focal points, and he knows Temodar can’t do this nearly as well because Temodar actually weakens t-cells.